Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: evidence for synergistic effects

Endocannabinoids modulate eating behavior; hence, endocannabinoid genes may contribute to the biological vulnerability to eating disorders. The rs1049353 (1359 G/A) single nucleotide polymorphism (SNP) of the gene coding the endocannabinoid CB1 receptor (CNR1) and the rs324420 (cDNA 385C to A) SNP of the gene coding fatty acid amide hydrolase (FAAH), the major degrading enzyme of endocannabinoids, have been suggested to have functional effects on mature proteins. Therefore, we explored the possibility that those SNPs were associated to anorexia nervosa and/or bulimia nervosa. The distributions of the CNR1 1359 G/A SNP and of the FAAH cDNA 385C to A SNP were investigated in 134 patients with anorexia nervosa, 180 patients with bulimia nervosa and 148 normal weight healthy controls. Additive effects of the two SNPs in the genetic susceptibility to anorexia nervosa and bulimia nervosa were also tested. As compared to healthy controls, anorexic and bulimic patients showed significantly higher frequencies of the AG genotype and the A allele of the CNR1 1359 G/A SNP. Similarly, the AC genotype and the A allele of the FAAH cDNA 385C to A SNP were significantly more frequent in anorexic and bulimic individuals. A synergistic effect of the two SNPs was evident in anorexia nervosa but not in bulimia nervosa. Present findings show for the first time that the CNR1 1359 G/A SNP and the FAAH cDNA 385C to A SNP are significantly associated to anorexia nervosa and bulimia nervosa, and demonstrate a synergistic effect of the two SNPs in anorexia nervosa.

[1]  T. Meitinger,et al.  Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa , 2008, Child and adolescent psychiatry and mental health.

[2]  M. Maj,et al.  Genetic susceptibility to eating disorders: associated polymorphisms and pharmacogenetic suggestions. , 2008, Pharmacogenomics.

[3]  Walter Heindel,et al.  Cannabinoid receptor 1 (CNR1) gene: Impact on antidepressant treatment response and emotion processing in Major Depression , 2008, European Neuropsychopharmacology.

[4]  M. Maj,et al.  Neuroendocrine dysregulation of food intake in eating disorders , 2008, Regulatory Peptides.

[5]  Guang Yong Zou,et al.  On the estimation of additive interaction by use of the four-by-two table and beyond. , 2008, American journal of epidemiology.

[6]  V. Marzo,et al.  Endocannabinoids and the control of energy balance , 2007, Trends in Endocrinology & Metabolism.

[7]  F Xavier Pi-Sunyer,et al.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.

[8]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[9]  T. Cassano,et al.  Correction for Gobbi et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Gorzalka,et al.  Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test , 2005, European Neuropsychopharmacology.

[11]  Jacqueline K. Wittke-Thompson,et al.  Rational inferences about departures from Hardy-Weinberg equilibrium. , 2005, American journal of human genetics.

[12]  M. Maj,et al.  Blood Levels of the Endocannabinoid Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in Bulimia Nervosa , 2005, Neuropsychopharmacology.

[13]  B. Cravatt,et al.  Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. , 2004, Human molecular genetics.

[14]  M. Rutkowska,et al.  Antidepressant--like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors. , 2004, Acta poloniae pharmaceutica.

[15]  K. Kanyas,et al.  Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: Differences between restricting and bingeing/purging subtypes , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[16]  F. Fumoux,et al.  Hemoglobin C is associated with reduced Plasmodium falciparum parasitemia and low risk of mild malaria attack. , 2003, Human molecular genetics.

[17]  T. Freund,et al.  The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety , 2002, The European journal of neuroscience.

[18]  E. Berry,et al.  Tetrahydrocannabinol and endocannabinoids in feeding and appetite. , 2002, Pharmacology & therapeutics.

[19]  B. Cravatt,et al.  A missense mutation in human fatty acid amide hydrolase associated with problem drug use , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Samochowiec,et al.  Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. , 2002, Drug and alcohol dependence.

[21]  M. Parmentier,et al.  Involvement of CB1 cannabinoid receptors in emotional behaviour , 2002, Psychopharmacology.

[22]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[23]  L. Petrocellis,et al.  Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action , 1998, Trends in Neurosciences.

[24]  M. First,et al.  Structured clinical interview for DSM-IV axis I disorders : SCID-I : clinical version : scoresheet , 1997 .

[25]  M. First,et al.  Structured clinical interview for DSM-IV axis I disorders : SCID-I: clinical version : administration booklet , 1996 .

[26]  W. Dixon,et al.  BMDP statistical software , 1983 .